IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
About the Study
Currently Recruiting: Participants
Study Drug/Intervention: Thoracic endovascular aortic repair (TEVAR) versus medical therapy
Anticipated Sample Size: 1,140 patients
Study Timeline: This study is anticipated to run from July 2023 through June 2030
ClinicalTrials.gov ID: NCT06087029
Study Objective
IMPROVE-AD aims to understand how best to treat type B aortic dissection.
Inclusion & Exclusion Criteria
Participants must be at least 21 years old, have received a diagnosis of type B aortic dissection in the last six weeks, not have a genetic condition that can affect the aorta (such a Marfan syndrome or Vascular Ehlers-Danlos syndrome), and be receiving treatment at a participating hospital.
Learn More
To learn more about IMPROVE-AD, visit the study website.